{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T04:57:50Z","timestamp":1786597070081,"version":"build-2736575974"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Lymphoplasmapheresis (LPE) is a treatment that combines traditional plasma exchange and lymphocyte removal technique. It has been applied to treat a variety of autoimmune diseases, but its application value in the treatment of severe myasthenia gravis (MG) is not yet clear. Therefore, the aim of this study was to investigate the efficacy and safety of LPE in severe MG.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Clinical data of 123 severe patients with MG (Myasthenia Gravis Foundation of America Clinical Classification, Class IV) who received LPE treatment were included in a retrospective analysis. Efficacy was evaluated by the change of Quantitative Myasthenia Gravis score (QMGS) before and after treatment. Univariate and multivariate logistic regression analysis was used to explore clinical factors affecting efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 220 replacements were performed in 123 patients, with an average of 1.79 replacements per patient. The overall safety of LPE was good, and no serious adverse reactions occurred. After treatment, the mean QMGS of patients decreased significantly, from 23.40 \u00b1 4.25 points before treatment to 17.93 \u00b1 5.61 points after treatment, a decrease of 5.47 \u00b1 4.16 points. 75.6% of patients experienced remission of clinical symptoms. During a 2-month follow-up of 64 patients, a progressive improvement in QMGS was found. Each muscle group involved in MG responded well to LPE treatment. In addition, LPE significantly reduced the levels of AChR-Ab and inflammatory cytokines in patients. Age \u2265 50 years and co-infection were unfavorable factors affecting the efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In this study cohort, LPE is safe for the treatment of severe MG and achieves good treatment outcome with fewer replacements. In patients with MG, the avoidance and timely control of infection are necessary. Our study provides a potential new treatment option for severe MG.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.1018509","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T04:43:55Z","timestamp":1665463435000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Application of lymphoplasmapheresis in the treatment of severe myasthenia gravis"],"prefix":"10.3389","volume":"13","author":[{"given":"Weiwei","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haobing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"917","DOI":"10.3389\/fimmu.2020.00917","article-title":"Complement inhibitor therapy for myasthenia gravis","volume":"11","author":"Albazli","year":"2020","journal-title":"Front Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"596981","DOI":"10.3389\/fneur.2020.596981","article-title":"Myasthenia gravis: autoantibody specificities and their role in Mg management","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"715036","DOI":"10.3389\/fimmu.2021.715036","article-title":"Clinical efficacy and safety of eculizumab for treating myasthenia gravis","volume":"12","author":"Xiao","year":"2021","journal-title":"Front Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"5755","DOI":"10.3390\/ijms22115755","article-title":"Fc-Receptor targeted therapies for the treatment of","volume":"22","author":"Keller","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","article-title":"Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German neurological society","volume":"263","author":"Melzer","year":"2016","journal-title":"J Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.3390\/jcm11061597","article-title":"Current treatment of myasthenia gravis","volume":"11","author":"Alhaidar","year":"2022","journal-title":"J Clin Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3389\/fneur.2020.00981","article-title":"From traditional to targeted immunotherapy in myasthenia gravis: prospects for research","volume":"11","author":"Mantegazza","year":"2020","journal-title":"Front Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/16078454.2021.2015842","article-title":"Effectiveness of lymphoplasmapheresis compared with therapeutic plasma exchange for thrombotic thrombocytopenic purpura: a retrospective evaluation","volume":"27","author":"Zhang","year":"2022","journal-title":"Hematology."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJM198206103062307","article-title":"A double-blind, controlled study of lymphoplasmapheresis versus sham apheresis in rheumatoid arthritis","volume":"306","author":"Wallace","year":"1982","journal-title":"N Engl J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/jca.2920020207","article-title":"Plasmapheresis versus lymphoplasmapheresis in rheumatoid arthritis: immunologic comparisons and literature review","volume":"2","author":"Wallace","year":"1984","journal-title":"J Clin Apher."},{"key":"B14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/jca.2920010105","article-title":"Use of lymphoplasmapheresis or plasmapheresis in the management of acute renal allograft rejection","volume":"1","author":"Kleinman","year":"1982","journal-title":"J Clin Apher."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e14092","DOI":"10.1111\/dth.14092","article-title":"Successful use of lymphoplasma exchange in a patient with acute generalized pustular psoriasis of von zumbusch","volume":"33","author":"Zhang","year":"2020","journal-title":"Dermatol Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e430","DOI":"10.1111\/1346-8138.15598","article-title":"Striking case of febrile ulceronecrotic mucha-habermann disease responding to lymphoplasmapheresis and methotrexate","volume":"47","author":"Wang","year":"2020","journal-title":"J Dermatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"106","DOI":"10.14715\/cmb\/2017.63.10.17","article-title":"Clinical efficacy and mechanism of lymphoplasma exchange in the treatment of guillain-barre syndrome","volume":"63","author":"Luo","year":"2017","journal-title":"Cell Mol Biol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.21037\/apm-21-177","article-title":"The efficacy of therapeutic apheresis in patients with refractory neuromyelitis optica spectrum disorders: a single-center retrospective study","volume":"10","author":"Zhang","year":"2021","journal-title":"Ann Palliat Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis score","volume":"841","author":"Barohn","year":"1998","journal-title":"Ann N Y Acad Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/cei.12217","article-title":"Myasthenia gravis: an update for the clinician","volume":"175","author":"Sieb","year":"2014","journal-title":"Clin Exp Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"116648","DOI":"10.1016\/j.jns.2019.116648","article-title":"Maintenance immunosuppression in myasthenia gravis, an update","volume":"410","author":"Morren","year":"2020","journal-title":"J Neurol Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/0022-510X(83)90096-5","article-title":"Anti-Acetylcholine receptor antibodies in myasthenia gravis. Part 2. Clinical and serological follow-up of individual patients","volume":"58","author":"Oosterhuis","year":"1983","journal-title":"J Neurol Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/nyas.13591","article-title":"An imbalance between regulatory T cells and T helper 17 cells in acetylcholine receptor-positive myasthenia gravis patients","volume":"1413","author":"Villegas","year":"2018","journal-title":"Ann N Y Acad Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/cei.13546","article-title":"Roles of cytokines and T cells in the pathogenesis of myasthenia gravis","volume":"203","author":"Uzawa","year":"2021","journal-title":"Clin Exp Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"803101","DOI":"10.3389\/fimmu.2021.803101","article-title":"Gut microbiota as regulators of Th17\/Treg balance in patients with myasthenia gravis","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1006\/jaut.2002.0618","article-title":"Anti-Tnf-Alpha antibodies suppress the development of experimental autoimmune myasthenia gravis","volume":"19","author":"Duan","year":"2002","journal-title":"J Autoimmun."},{"key":"B30","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jaut.2011.05.006","article-title":"Complement and cytokine based therapeutic strategies in myasthenia gravis","volume":"37","author":"T\u00fcz\u00fcn","year":"2011","journal-title":"J Autoimmun."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of Ivig and plex in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology."},{"key":"B32","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia gravis clinical study group","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/ene.14153","article-title":"Serious infections in patients with myasthenia gravis: population-based cohort study","volume":"27","author":"Kassardjian","year":"2020","journal-title":"Eur J Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/mus.26032","article-title":"Infections and the relationship to treatment in neuromuscular autoimmunity","volume":"57","author":"Prior","year":"2018","journal-title":"Muscle Nerve."},{"key":"B35","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/mus.26689","article-title":"Factors associated with acute exacerbations of myasthenia gravis","volume":"60","author":"Gummi","year":"2019","journal-title":"Muscle Nerve."},{"key":"B36","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1055\/s-0036-1592106","article-title":"Getting rid of weakness in the ICU: an updated approach to the acute management of myasthenia gravis and Guillain-Barr\u00e9 syndrome","volume":"36","author":"Lizarraga","year":"2016","journal-title":"Semin Neurol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1177\/0300060516669893","article-title":"Predictors of extubation outcomes following myasthenic crisis","volume":"44","author":"Liu","year":"2016","journal-title":"J Int Med Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1212\/WNL.40.5.786","article-title":"The relationship of age to outcome in myasthenia gravis","volume":"40","author":"Donaldson","year":"1990","journal-title":"Neurology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/mus.26132","article-title":"Survival and mortality of adult-onset myasthenia gravis in the population of belgrade, Serbia","volume":"58","author":"Basta","year":"2018","journal-title":"Muscle Nerve."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e1171","DOI":"10.1212\/WNL.0000000000008903","article-title":"Clinical and therapeutic features of myasthenia gravis in adults based on age at onset","volume":"94","author":"Cort\u00e9s-Vicente","year":"2020","journal-title":"Neurology."},{"key":"B41","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/acn3.51492","article-title":"Drug-Refractory myasthenia gravis: clinical characteristics, treatments, and outcome","volume":"9","author":"Cort\u00e9s-Vicente","year":"2022","journal-title":"Ann Clin Transl Neurol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.1018509\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T04:43:58Z","timestamp":1665463438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.1018509\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,11]]},"references-count":41,"alternative-id":["10.3389\/fneur.2022.1018509"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.1018509","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,11]]},"article-number":"1018509"}}